Rhode Island Senate Bill S2870

Rhode Island 2022 Regular Session

• Introduced: 4/12/22
• Passed: 4/12/22

Caption

Senate Resolution Proclaiming May 1st Through May 8th To Be "tardive Dyskinesia (td) Awareness Week" In The State Of Rhode Island

Impact

The proclamation of Tardive Dyskinesia Awareness Week is expected to foster greater recognition of the disorder amongst the general public and healthcare professionals. As TD can develop after prolonged use of DRBAs, encouraging regular screenings and informing both patients and practitioners about the disorder is crucial. Instituting this awareness week could lead to better diagnosis rates and ultimately improve the quality of life for those afflicted with TD in Rhode Island. The resolution aligns with the American Psychiatric Association's recommendations to promote regular screenings for patients on these medications.

Summary

Senate Bill S2870 is a resolution that aims to declare May 1st through May 8th as 'Tardive Dyskinesia Awareness Week' in the state of Rhode Island. The bill was introduced by Senator Joshua Miller and emphasizes the need for increased awareness and understanding of Tardive Dyskinesia (TD), a condition often resulting from treatment with dopamine receptor blocking agents (DRBAs) commonly prescribed for various mental health issues. The resolution highlights the serious implications of TD, acknowledging the considerable number of individuals affected by it across the country, estimated at over 600,000 Americans.

Sentiment

The sentiment surrounding S2870 is predominantly positive, with support expressed for enhancing awareness of Tardive Dyskinesia and its impacts. Advocates for mental health view this resolution as a crucial step toward understanding and addressing the challenges faced by individuals with TD. The bill addresses a significant public health concern, promoting dialogue and education about TD and its connection to common mental health treatments.

Contention

Notable points of contention surrounding the resolution may center on the broader issue of mental health treatment practices, particularly the use of DRBAs and their long-term impacts. While the resolution itself does not propose any legislative changes regarding medication use, it opens the floor for discussions about treatment ethics, patient monitoring, and the need for ongoing research into safer alternatives for those suffering from mental health conditions. Some may argue about the sufficiency of current protocols for managing and monitoring the side effects of such treatments.